http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107982538-B
Outgoing Links
Predicate | Object |
---|---|
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
filingDate | 2017-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-107982538-B |
titleOfInvention | Pharmaceutical composition and application thereof |
abstract | The invention relates to the field of cellular immunotherapy of tumors, in particular to a pharmaceutical composition and application thereof, wherein the pharmaceutical composition comprises a drug specifically targeting renal tumor GPC3, and the drug specifically targeting renal tumor GPC3 comprises any one or combination of at least two of CAR-T cells, anti-GPC 3 antibodies, TCR-T cells targeting GPC3, DC-CIK targeting GPC3 or siRNA targeting silencing GPC 3. The invention discovers that GPC3 can be used as a novel target antigen of nephroblastoma, and the medicine composition can effectively kill and inhibit the nephroblastoma. |
priorityDate | 2017-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 692.